Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093510 | 0.89 | TAAR1 (0.50) | ALDH1A1LMNATAAR1SMN1; SMN2PLAU | |
| SCHEMBL22526946 | 0.88 | FAAH (0.53) | ALDH1A1LMNATAAR1SMN1; SMN2 | |
| SCHEMBL608865 | 0.87 | ALDH1A1 (0.62) | ALDH1A1LMNACAPN1PRMT1PLK1 | |
| Cadaverine Tartrate SCHEMBL9938636 | 0.83 | ALDH1A1 (0.44) | ALDH1A1LMNATAAR1CAPN1PRMT1 | |
| SCHEMBL364573 | 0.83 | FFAR1 (0.55) | ALDH1A1LMNATAAR1CAPN1PRMT1 | |
| SCHEMBL28039008 | 0.82 | IAPP (0.53) | ALDH1A1TAAR1PLK1CYP4F2CYP4A11 | |
| Butane SCHEMBL10453910 | 0.82 | CA2 (0.53) | ALDH1A1LMNATAAR1CAPN1CA2 | |
| SCHEMBL4684568 | 0.82 | ALDH1A1 (0.59) | ALDH1A1LMNACA2 | |
| SCHEMBL43642 | 0.80 | PLA2G10 (0.46) | ALDH1A1LMNACAPN1PRMT1CYP4F2 | |
| SCHEMBL11444235 | 0.80 | ALDH1A1 (0.65) | ALDH1A1LMNATAAR1SMN1; SMN2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016097394-A1 | BICYCLIC SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | claimed |
| CN-103288669-A | Atrolactic acid amide derivative and applications thereof | UNIV NANKAI | 2013-09-11 | — | — | CN | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| US-11053270-B2 | Heterobivalent ligands suitable for use in the treatment of Parkinson's disease | T C ISTANBUL MEDIPOL UENIVERSITESI (TR) | 2021-07-06 | — | — | US | disclosed |
| US-20210147421-A1 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | T C ISTANBUL MEDIPOL UENIVERSITESI (TR) | 2021-05-20 | — | — | US | disclosed |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-08-25 | — | — | US | disclosed |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | ALDH1A1 3935/4885LMNA 770/4885TAAR1 4447/4885 |
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | RORA, RORB, RORC | ALDH1A1 590/4885LMNA 4403/4885TAAR1 1111/4885 |
| US-20210147421-A1 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | PARK7, SNCA, NLN | ALDH1A1 3784/4885LMNA 4720/4885TAAR1 675/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | ALDH1A1 3935/4885LMNA 770/4885TAAR1 4447/4885 |
| US-11053270-B2 | Heterobivalent ligands suitable for use in the treatment of Parkinson's disease | PARK7, SNCA, NLN | ALDH1A1 3784/4885LMNA 4720/4885TAAR1 675/4885 |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | ALDH1A1 587/4885LMNA 4400/4885TAAR1 1155/4885 |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | RORA, RORB, RORC | ALDH1A1 587/4885LMNA 4400/4885TAAR1 1155/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | ALDH1A1 3935/4885LMNA 770/4885TAAR1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.